News archive

June 2021

• Media ReleaseJun 04, 2021
  Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
• Media ReleaseJun 04, 2021
  Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy
  Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell…
• Media ReleaseJun 04, 2021
  Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC
  Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta…
• Media ReleaseJun 03, 2021
  Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
  -- Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression…
• Media ReleaseJun 03, 2021
  Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
• Media ReleaseJun 03, 2021
  Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study
  Men who received 177Lu-PSMA-617 plus best standard of care had a 38% reduction in risk of death (median OS benefit of 4 months) and a 60% reduction in the risk of radiographic disease progression…
• Media ReleaseJun 02, 2021
  Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
• Media ReleaseJun 02, 2021
  Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
• Media ReleaseJun 02, 2021
  Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma
  Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion(1) Robust response observed in heavily pretreated patients in…
• Media ReleaseJun 02, 2021
  Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients
  MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS…
• Media ReleaseJun 01, 2021
  Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
• Media ReleaseJun 01, 2021
  Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis
  Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1)…